Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study

被引：0

作者：

Jie Xie

Jun Cao

Jing-fen Wang

Bai-hong Zhang

Xiao-hua Zeng

Hong Zheng

Yang Zhang

Li Cai

Yu-dong Wu

Qiang Yao

Xiao-chun Zhao

Wei-dong Mao

Ai-Mei Jiang

Shao-shui Chen

Shun-e Yang

Shu-sen Wang

Jian-hong Wang

Yue-yin Pan

Bi-yong Ren

Yan-ju Chen

Li-zhi Ouyang

Kai-jian Lei

Jing-hua Gao

Wen-he Huang

Zhan Huang

Tao Shou

Yan-ling He

Jing Cheng

Yang Sun

Wei-ming Li

Shu-de Cui

Xin Wang

Zhi-guo Rao

Hu Ma

Wei Liu

Xue-yong Wu

Wei-xi Shen

Fei-lin Cao

Ze-min Xiao

Biao Wu

Shu-yan Tian

Dong Meng

Peng Shen

Bi-yun Wang

Zhonghua Wang

Jian Zhang

Leiping Wang

Xi-chun Hu

机构：

[1] Fudan University Shanghai Cancer Center,Department of Medical Oncology

[2] Fudan University,Department of Oncology, Shanghai Medical College

[3] Linyi Tumor Hospital,undefined

[4] Lanzhou Military General Hospital of People’s Liberation Army,undefined

[5] Chongqing Cancer Hospital,undefined

[6] Liaocheng People’s Hospital,undefined

[7] The Affiliated Tumor Hospital of Harbin Medical University,undefined

[8] Jiangxi Cancer Hospital,undefined

[9] Tianjin People’s Hospital,undefined

[10] The First Affiliated Hospital Of University Of South China,undefined

[11] The Affiliated Jiangyin Hospital of Southeast University Medical College,undefined

[12] First Affiliated Hospital of Kunming Medical University,undefined

[13] Binzhou Medical School Affiliated Hospital,undefined

[14] Tumour Hospital Affiliated To Xinjiang Medical University,undefined

[15] Sun Yat-sen University Cancer Center,undefined

[16] Nantong Tumor Hospital,undefined

[17] The First Affiliated Hospital Of Anhui Medical University,undefined

[18] Chongqing Three Gorges Central Hospital,undefined

[19] Hainan General Hospital,undefined

[20] Hunan Cancer Hospital,undefined

[21] The Second People’s Hospital of Yibin,undefined

[22] Cangzhou Central Hospital,undefined

[23] Cancer Hospital of Shantou University Medical College,undefined

[24] Yue Bei People’s Hospital,undefined

[25] The First People’s Hospital of Yunnan Province,undefined

[26] Peking University Shenzhen Hospital,undefined

[27] Huazhong University of Science and Technology Wuhan Union Hospital,undefined

[28] People’s Hospital of Sanya,undefined

[29] The Third Affiliated Hospital of Guangzhou Medical University,undefined

[30] Henan Cancer Hospital,undefined

[31] Zhongshan Hospital Affiliated To Xiamen University,undefined

[32] Wuhan General Hospital of Guangzhou Military,undefined

[33] Affiliated Hospital of Zunyi Medical College,undefined

[34] Affiliated Hospital of Beihua University,undefined

[35] Jing’an District Centre Hospital of Shanghai,undefined

[36] Shenzhen People’s Hospital,undefined

[37] Taizhou Hospital of Zhejiang Province,undefined

[38] The First People’s Hospital of Changde City,undefined

[39] The First Affiliated Hospital of Nanchang University,undefined

[40] The Centre Hospital of Siping City,undefined

[41] Wu Xi No.4 People’s Hospital,undefined

[42] The First Affiliated Hospital Of Zhejiang University,undefined

来源：

Breast Cancer Research and Treatment | 2018年 / 168卷

关键词：

Breast cancer; Multicenter study; PEG-rhG-CSF; Neutropenia;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：389 / 399

页数：10

共 28 条

[1] Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study
Xie, Jie
Cao, Jun
Wang, Jing-fen
Zhang, Bai-hong
Zeng, Xiao-hua
Zheng, Hong
Zhang, Yang
Cai, Li
Wu, Yu-dong
Yao, Qiang
Zhao, Xiao-chun
Mao, Wei-dong
Jiang, Ai-Mei
Chen, Shao-shui
Yang, Shun-e
Wang, Shu-sen
Wang, Jian-hong
Pan, Yue-yin
Ren, Bi-yong
Chen, Yan-ju
Ouyang, Li-zhi
Lei, Kai-jian
Gao, Jing-hua
Huang, Wen-he
Huang, Zhan
Shou, Tao
He, Yan-ling
Cheng, Jing
Sun, Yang
Li, Wei-ming
Cui, Shu-de
Wang, Xin
Rao, Zhi-guo
Ma, Hu
Liu, Wei
Wu, Xue-yong
Shen, Wei-xi
Cao, Fei-lin
Xiao, Ze-min
Wu, Biao
Tian, Shu-yan
Meng, Dong
Shen, Peng
Wang, Bi-yun
Wang, Zhonghua
Zhang, Jian
Wang, Leiping
Hu, Xi-chun
BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : 389 - 399
[2] Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
Jiang, Yantao
Zhang, Ju
Zhong, Jianxin
Liao, Hao
Zhang, Jiayang
Liu, Yaxin
Liang, Yuehua
Li, Huiping
BMC CANCER, 2023, 23 (01)
[3] Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients
Yantao Jiang
Ju Zhang
Jianxin Zhong
Hao Liao
Jiayang Zhang
Yaxin Liu
Yuehua Liang
Huiping Li
BMC Cancer, 23
[4] PEG-rhG-CSF versus rhG-CSF in supporting neutrophil recovery after induction chemotherapy for patients with newly diagnosed acute lymphoblastic leukemia
Jin, Shumin
Chang, Mengyuan
Feng, Lei
Hao, Yiping
Li, Wei
Zhou, Ying
Jia, Ruinan
Liu, Tingting
Zhang, Di
Jiang, Huihui
Wang, Jingtao
Zhao, Chuanli
Ji, Chunyan
Ye, Jingjing
Ji, Min
ANNALS OF HEMATOLOGY, 2025, : 1039 - 1046
[5] PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study
Sun, Xu-Sheng
Wang, Zhe
Ren, Shu-Hua
Zhang, He-Lin
Liu, Li-Jun
Du, Hong-Bo
Liu, Xiao-Wei
Liu, Jun-Feng
THORACIC CANCER, 2022, 13 (17) : 2429 - 2435
[6] Efficacy, safety, and cost-effectiveness of pegylated PEG-rhg-CSF in pediatric patients receiving high-intensity chemotherapy: results from a phase II study
Huang, Junting
Zhu, Jia
Jiang, Lian
Xu, Jiaqian
Lin, Xiheng
Chang, Jian
Zhang, Xiaohong
Lu, Suying
Sun, Feifei
Wang, Juan
Que, Yi
Ye, Zhonglv
Yang, Lihua
Yuan, Xiuli
Cai, Weisong
Tian, Chuan
Wu, Yanpeng
He, Xiangling
Tang, Yan-Lai
Zhang, Yizhuo
FRONTIERS IN PHARMACOLOGY, 2024, 15
[7] Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy
Waller, CF
von Lintig, F
Daskalakis, A
Musahl, V
Lange, W
BONE MARROW TRANSPLANTATION, 1999, 24 (01) : 19 - 24
[8] Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy
CF Waller
F von Lintig
A Daskalakis
V Musahl
W Lange
Bone Marrow Transplantation, 1999, 24 : 19 - 24
[9] A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
Zhang, Qingyuan
Wang, Zhonghua
Yao, Wei
Wang, Shufang
Zhang, Gaochong
Chen, Jianmin
Hou, Qingsong
Li, Simon
Li, Hongsheng
Ye, Changsheng
Sun, Tao
Yang, Hongjian
Chen, Zhendong
Wang, Zhihong
Liu, Xiaoan
Geng, Cuizhi
Li, Xingrui
Zhang, Jin
Zheng, Hong
Shao, Zhimin
BMC CANCER, 2024, 24 (01)
[10] A multicenter phase II trial of primary prophylactic PEG- rhG-CSF in pediatric patients with solid tumors and non- Hodgkin lymphoma after chemotherapy: An interim analysis
Huang, Junting
Lu, Suying
Wang, Juan
Jiang, Lian
Luo, Xuequn
He, Xiangling
Wu, Yanpeng
Wang, Yi
Zhu, Xiuli
Chen, Jian
Tang, Yanlai
Chen, Keke
Tian, Xin
Shi, Boyun
Guo, Lanying
Zhu, Jia
Sun, Feifei
Zhen, Zijun
Zhang, Yizhuo
CANCER MEDICINE, 2023, 12 (13): : 14130 - 14137

← 1 2 3 →